ISI,  a provider of software and services for the life sciences industry,  announced that it has acquired Apyx, Inc. The merger adds  to ISI’s growing professional services business and enhances the company’s range of offerings in submissions management and outsourcing. The two companies’ shared commitment to customer service and responsiveness make the merger a  fit.  

ISI currently provides 13 out of the top 20 pharmaceutical companies with ongoing, repeat services. Over the last decade, the company has helped biopharmaceutical companies all over the world bring dozens of therapies through regulatory approval to patients in need. The acquisition helps ISI strengthen its capabilities to offer clients a mix of process, technology, data and operational services that respond to today’s complex submission environment.

 “With ISI’s deep resources and expertise in Europe and Asia, we will be able to address the diverse range of submission requirements across the globe," said Ken VanLuvanee, CEO, President and Founder of Apyx, Inc.

  ISI makes the acquisition at a time of flux for the pharmaceutical industry. In the wake of transformational new regulations and a host of economic and competitive factors, life sciences firms are dealing with a complex global marketplace they have never seen before. Diverse and ever-changing regulatory standards across regions, the need to expand into emerging markets, and increasing pressure to collaborate with partners and oversee local operations are all contributing to the new era of unparalleled complexity. 

With the acquisition of Apyx, ISI will deliver more efficient and standardized processes and systems, enable operational alignment around the globe, and facilitate a more effective exchange of information to help clients navigate these new challenges. 